Teva Pharmaceutical Industries Ltd. ADR (TEVA): Price and Financial Metrics

Teva Pharmaceutical Industries Ltd. ADR (TEVA): $16.81

0.47 (+2.88%)

POWR Rating

Component Grades








Add TEVA to Watchlist
Sign Up

TEVA Price/Volume Stats

Current price $16.81 52-week high $17.69
Prev. close $16.34 52-week low $8.06
Day low $16.31 Volume 7,446,800
Day high $16.88 Avg. volume 10,343,782
50-day MA $16.69 Dividend yield N/A
200-day MA $12.75 Market Cap 19.04B

TEVA Stock Price Chart Interactive Chart >

Teva Pharmaceutical Industries Ltd. ADR (TEVA) Company Bio

Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces, and markets, generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Established in 1901, the company markets 3,500 generic and proprietary products to 60 countries worldwide. Teva competes against other large pharmaceutical companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline. Kare Schulz currently serves as Teva’s President, Chairman of the Board, and Chief Executive Officer, overseeing an international workforce of around 38,000 employees.

TEVA Latest News Stream

Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream

Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, December 28, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time).

Yahoo | December 28, 2023

HSBC Sees Opportunity in These 2 Biopharma Giants Ahead of the 2024 Elections

The silly season is upon us. Not the holidays – but the election. We’re less than 11 months out from the Presidential vote, and the first primary, the Iowa GOP caucus, is less than 30 days away. Election years are the ‘known unknown’ of the US economy. We know they’re coming, we know the results can change everything, we know that every economic sector will react differently – but we never truly know how those changes will shake out. This cyclical truth of politics and financial markets informs

Yahoo | December 26, 2023

Here’s Why Teva Pharmaceutical Industries Limited (TEVA) Rose in Q3

Sound Shore Management, an investment management firm, has released its investor letter for the third quarter of 2023. A copy of the same can be downloaded here. In the third quarter, the Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) declined 2.01% and 1.94%, respectively outperforming the Russell 1000 Value Index (Russell Value) which […]

Yahoo | December 21, 2023

My 5 Largest Portfolio Holdings for 2024

This mix of growth and value stocks appears set to outperform -- and hopefully makes me a lot richer in the process.

Yahoo | December 15, 2023

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

TEL AVIV, Israel, December 14, 2023--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma.

Yahoo | December 14, 2023

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo -0.88%
3-mo 30.51%
6-mo 40.20%
1-year 97.53%
3-year 88.88%
5-year 118.88%
YTD 61.02%
2023 14.47%
2022 13.86%
2021 -16.99%
2020 -1.53%
2019 -36.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!